Last reviewed · How we verify
Gemcitabine, Docetaxel, or Capecitabine
Gemcitabine, Docetaxel, or Capecitabine is a Chemotherapy combination (nucleoside analog, taxane, fluoropyrimidine) Small molecule drug developed by Shanghai Miracogen Inc.. It is currently in Phase 3 development for Advanced or metastatic solid tumors (specific indication under investigation in phase 3 trial).
This is a combination of three chemotherapy agents that work through different mechanisms to inhibit cancer cell growth and division.
This is a combination of three chemotherapy agents that work through different mechanisms to inhibit cancer cell growth and division. Used for Advanced or metastatic solid tumors (specific indication under investigation in phase 3 trial).
At a glance
| Generic name | Gemcitabine, Docetaxel, or Capecitabine |
|---|---|
| Sponsor | Shanghai Miracogen Inc. |
| Drug class | Chemotherapy combination (nucleoside analog, taxane, fluoropyrimidine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination. Docetaxel is a taxane that stabilizes microtubules and prevents cell division. Capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase and gets incorporated into RNA and DNA. Together, these agents provide multi-modal cytotoxic activity against rapidly dividing cancer cells.
Approved indications
- Advanced or metastatic solid tumors (specific indication under investigation in phase 3 trial)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Fatigue
- Hand-foot syndrome
- Peripheral neuropathy
Key clinical trials
- Metastasis-directed Therapy for Oligometastases of Breast Cancer (PHASE3)
- A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (PHASE3)
- Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis (PHASE4)
- A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (PHASE3)
- JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects (PHASE3)
- A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (PHASE3)
- MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (PHASE2)
- JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine, Docetaxel, or Capecitabine CI brief — competitive landscape report
- Gemcitabine, Docetaxel, or Capecitabine updates RSS · CI watch RSS
- Shanghai Miracogen Inc. portfolio CI
Frequently asked questions about Gemcitabine, Docetaxel, or Capecitabine
What is Gemcitabine, Docetaxel, or Capecitabine?
How does Gemcitabine, Docetaxel, or Capecitabine work?
What is Gemcitabine, Docetaxel, or Capecitabine used for?
Who makes Gemcitabine, Docetaxel, or Capecitabine?
What drug class is Gemcitabine, Docetaxel, or Capecitabine in?
What development phase is Gemcitabine, Docetaxel, or Capecitabine in?
What are the side effects of Gemcitabine, Docetaxel, or Capecitabine?
Related
- Drug class: All Chemotherapy combination (nucleoside analog, taxane, fluoropyrimidine) drugs
- Manufacturer: Shanghai Miracogen Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic solid tumors (specific indication under investigation in phase 3 trial)
- Compare: Gemcitabine, Docetaxel, or Capecitabine vs similar drugs
- Pricing: Gemcitabine, Docetaxel, or Capecitabine cost, discount & access